Tumoral C2 Regulates the Tumor Microenvironment by Increasing the Ratio of M1/M2 Macrophages and Tertiary Lymphoid Structures to Improve Prognosis in Melanoma

Gengpu Zhang,Shengnan Li,Wanyi Xiao,Chao Zhang,Ting Li,Zhichao Liao,Haotian Liu,Ruwei Xing,Wei Yao,Jilong Yang

DOI: https://doi.org/10.3390/cancers16050908

2024-02-24

Cancers

Abstract:Immunotherapy is an essential therapy for individuals with advanced melanoma. However, not all patients respond to such treatment due to individual differences. We conducted a multidimensional analysis using transcriptome data from our center, as well as publicly available databases. We found that effective nivolumab treatment led to an upregulation of C2 levels, and higher levels following treatment are indicative of a good outcome. Through bioinformatics analyses and immunofluorescence, we identified a correlation between C2 and M1 macrophages. To further investigate the role of C2 in melanoma, we constructed subcutaneous tumorigenic models in C57BL/6 mice. The tumors in the C2 overexpression group exhibited significantly smaller sizes. Flow cytometric analysis of the mouse tumors demonstrated enhanced recruitment of macrophages, particularly of the M1 subtype, in the overexpression group. Moreover, single-cell RNA sequencing analysis revealed that C2-positive tumor cells exhibited enhanced communication with immune cells. We co-cultured tumor cell supernatants with macrophages in vitro and observed the induction of M1 subtype polarization. In addition, we discovered a close correlation between C2 and tertiary lymphoid structures. C2 has been demonstrated to exert a protective effect, mediated by its ability to modulate the tumor microenvironment. C2 serves as a prognostic marker for melanoma and can be employed to monitor the efficacy of immunotherapy.

oncology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to explore the role of complement C2 in melanoma and its impact on the tumor microenvironment (TME). Specifically, the researchers hope to identify indicators that can monitor patient prognosis and the effectiveness of immunotherapy. By analyzing the transcriptome data of patients receiving anti-PD-1 immunotherapy, they found that complement C2 was upregulated after effective treatment, and patients with high C2 expression had longer survival periods. Further studies showed that tumors with high C2 expression had an increased proportion of M1 macrophages and tertiary lymphoid structures (TLSs), which may be key factors leading to a good prognosis. ### Main Research Content 1. **Clinical Value**: - Researchers found that C2 expression was upregulated after effective nivolumab treatment by analyzing paired samples from the CA209-038 study. - Patients with high C2 expression had longer survival periods. - In multiple independent datasets, high C2 levels were associated with better survival prognosis. 2. **Immune Status**: - Differential gene expression analysis (DEGs) revealed that immune-related genes were significantly upregulated in the high C2 expression group. - Functional enrichment analysis showed that C2 is related to pathways such as antigen processing and presentation, phagosome, Toll-like receptor signaling, and JAK-STAT signaling. - Immune score analysis indicated higher immune component infiltration in the high C2 expression group. - Immune cell subset analysis showed an increased proportion of M1 macrophages, a decreased proportion of M2 macrophages, and increased levels of CD8+ T cells, activated CD4+ T cells, and plasma cells in melanoma tissues with high C2 expression. 3. **In Vivo Experiments**: - A stable C2-expressing B16 mouse melanoma cell line was constructed, and a subcutaneous tumor model was established. - Tumor growth was significantly slowed in C2 overexpressing tumors. - Flow cytometry analysis showed an increased proportion of M1 macrophages and a decreased proportion of M2 macrophages in C2 overexpressing tumors. 4. **In Vitro Experiments**: - Single-cell sequencing technology revealed more frequent communication between C2-positive tumor cells and immune cells. - Co-culture experiments showed that C2 can induce THP-1 cells to differentiate into M1 macrophages. - Overexpressing C2 in A375 cells promoted the differentiation of M0 macrophages into M1 macrophages. ### Conclusion Complement C2 plays a protective role in melanoma by regulating the M1/M2 macrophage ratio in the tumor microenvironment and promoting the formation of tertiary lymphoid structures, thereby improving patient prognosis. C2 can serve as a prognostic marker for melanoma and be used to monitor the effectiveness of immunotherapy.

Tumoral C2 Regulates the Tumor Microenvironment by Increasing the Ratio of M1/M2 Macrophages and Tertiary Lymphoid Structures to Improve Prognosis in Melanoma

LMD-03. Single Cell Analysis Reveals How Therapy Remodels the Tumor Microenvironment in Melanoma CNS Metastases and Uncovers a Novel Predictor of Improved Survival

<i>CCND1</i> Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment

Single-Cell Analysis Reveals The Interaction Between M2 Macrophages And Nk Cells Underlying Immune Types Associated With Cancer Immunotherapy Response

Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Regulatory T cells subgroups in the tumor microenvironment cannot be overlooked: Their involvement in prognosis and treatment strategy in melanoma

CCND1 amplification profiling identifies a subtype of melanoma associated with poor survival and an immunosuppressive tumor microenvironment.

MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinoma

Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Exploring Tumor Immune Microenvironment and Its Associations With Molecular Characteristics in Melanoma

Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment

Tumor Microenvironment Remodeling And Tumor Therapy Based On M2-Like Tumor Associated Macrophage-Targeting Nano-Complexes

Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma

Modulation Of T-Cell Activation By Malignant Melanoma Initiating Cells

A Novel Gene Prognostic Signature Lymphocyte Cytosolic Protein 2 Regulates Melanoma Progression by Activating Tumor-Infiltrating CD8+ T-cells Through the Interferon Regulatory Factor 5 Signaling Pathway

CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment

Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.